Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FOLFOX and Bevacizumab With or Without Irinotecan in First-line Treatment for Metastatic Colorectal Cancer. A Randomized Phase II Study

NCT01321957 is registered in ClinicalTrials.gov with Martin-Luther-Universität Halle-Wittenberg as lead sponsor.

NCT NCT01321957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01321957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FOLFOX and Bevacizumab With or Without Irinotecan in First-line Treatment for Metastatic Colorectal Cancer. A Randomized Phase II Study
Lead sponsor
Martin-Luther-Universität Halle-Wittenberg
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2011
Completion date
August 15, 2018
Enrollment
250 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer